At Annogen we use our SuRE™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein and virus production. In addition, we offer the AIM™ service to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches typically enable big improvements in any biomedical strategy involving the (over-) expression of genes.  

​

Our SuRE™ technology does not deliver AI-based predictions that need to be verified by the customer but instead delivers the results of millions of actual wet-lab measurements in relevant (primary) cells and in vivo models. Our activities are based on two core proprietary technologies:

​

1. SuRE™ Technology and Screening services (bespoke promoters)

2. AIM™ integration site mapping service